Future Directions in Bladder Cancer Treatment: The Experts Weigh

Target Audience
Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists.

Statement of Need/Program Overview
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs. Neal Shore, Andrea Apolo, and Arjun Balar for this online on-demand activity as they dive into the latest data in bladder cancer therapies.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Monitor and review ongoing advanced bladder cancer trials with real time discussion of evidence-based data about new therapies.